Vyvanse Regret, Stopping, and Restarting: What Real Users and Clinical Data Actually Show

What the label says about stopping

Lisdexamfetamine is an inactive prodrug that the body converts to dextroamphetamine, mostly in red blood cells, by a route that does not involve cytochrome P450 enzymes [1]. Amphetamines can produce physical dependence and tolerance, and the Vyvanse label states that withdrawal after prolonged use can include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite and psychomotor changes [1].

The label carries a single boxed warning, for abuse, misuse and addiction: lisdexamfetamine has a high potential for abuse and misuse, which can lead to a substance use disorder including addiction, and misuse can cause overdose and death, with greater risk at higher doses or with snorting or injection [1]. Being a prodrug does not remove that risk. In an abuse-liability study of 38 people with a history of drug abuse, Vyvanse 100 mg produced significantly less drug liking than immediate-release d-amphetamine 40 mg, while Vyvanse 150 mg produced drug liking similar to d-amphetamine 40 mg and diethylpropion 200 mg [1].

Who stops in trials, and why

Controlled trials give the cleanest numbers on how often side effects end treatment. In the 4-week adult ADHD trial, 6% (21 of 358) of patients on lisdexamfetamine stopped because of adverse reactions versus 2% (1 of 62) on placebo [1]. The reactions most often leading to discontinuation were insomnia (2%), then tachycardia, irritability, hypertension, headache, anxiety and dyspnea (1% each) [1]. In children aged 6 to 12 the discontinuation rate for adverse reactions was 8% (18 of 218) versus 0% (0 of 72) on placebo, and in adolescents aged 13 to 17 it was 3% (7 of 233) versus 1% (1 of 77) [1].

The reactions themselves are common in adults: decreased appetite 27% versus 2% on placebo, insomnia 27% versus 8%, and dry mouth 26% versus 3% [1]. In adults with binge eating disorder, dry mouth was 36% versus 7% and insomnia 20% versus 8% [1]. A 2025 meta-analysis of 93 randomized trials of methylphenidate, lisdexamfetamine and other amphetamines found a higher risk of any adverse event with stimulants than with placebo (risk ratio 1.34, 90% CI 1.27 to 1.41), and the finding held separately for lisdexamfetamine [3].

On the benefit side, in the 420-adult ADHD trial, 29% of the placebo group were rated improved on the CGI-I at endpoint versus 57% at 30 mg, 62% at 50 mg and 61% at 70 mg [4]. These were 4-week trials, so they capture early discontinuation only.

Tolerance and continued treatment

The label lists tolerance as a possible consequence of amphetamine use [1]. Its dose instructions allow adjustments of 10 mg or 20 mg at roughly weekly intervals up to 70 mg a day for ADHD, and 20 mg steps toward a target of 50 to 70 mg a day for binge eating disorder [1]. The most direct controlled evidence on continuing treatment is in binge eating disorder, where the 26-week randomized-withdrawal phase showed far less relapse in adults who kept taking lisdexamfetamine than in those switched to placebo [2].

Stopping treatment for binge eating disorder

The label directs that Vyvanse be discontinued if binge eating does not improve [1]. For people in whom it does work, the relapse data are unusually clear. Four hundred eighteen adults entered a 12-week open-label phase at 50 or 70 mg, and 275 responders were then assigned to continue lisdexamfetamine (n=137) or switch to placebo (n=138) for up to 26 weeks [2]. Relapse occurred in 3.7% (5 of 136) on lisdexamfetamine versus 32.1% (42 of 131) on placebo, hazard ratio 0.09 (95% CI 0.04 to 0.23, P<.001) [2].

In the two pivotal 12-week trials, lisdexamfetamine 50 or 70 mg a day reduced binge eating days per week by 1.35 days (95% CI -1.70 to -1.01) in study 1 and 1.66 days (-2.04 to -1.28) in study 2 relative to placebo, both P<.001 [5]. Mean pulse rose 4.41 to 6.31 beats per minute [5].

How fast does lisdexamfetamine clear?

After an oral dose, lisdexamfetamine itself has a plasma half-life averaging under 1 hour, while the active dextroamphetamine has a half-life of about 10 to 11.3 hours in healthy adults and 8.6 to 9.5 hours in children aged 6 to 12 [1]. The label reports no accumulation at steady state in healthy adults, and about 96% of an oral dose is recovered in urine [1]. In fasted children, dextroamphetamine peaks about 3.5 hours after a capsule, and food delays that peak by about an hour without changing total exposure [1].

The label says a single dose should not be divided: opening a capsule means emptying and mixing the entire contents with yogurt, water or orange juice and consuming it immediately, and chewable tablets must be chewed thoroughly [1]. Capsules and chewable tablets can be substituted milligram for milligram [1].

Restarting after a break

The label's recommended starting dose for ADHD in adults and children aged 6 and older is 30 mg once every morning, adjusted by 10 mg or 20 mg at about weekly intervals to a recommended 30 to 70 mg a day, with 70 mg as the maximum [1]. For binge eating disorder the start is also 30 mg every morning, titrated in 20 mg steps at about weekly intervals to a target of 50 to 70 mg a day [1].

The label also sets out checks that come before and during treatment: an assessment for cardiac disease covering personal history, family history of sudden death or ventricular arrhythmia, and a physical exam; a family history and clinical evaluation for tics or Tourette's syndrome; and monitoring of blood pressure and pulse in every treated patient [1]. Stimulants raise blood pressure by a mean of about 2 to 4 mm Hg and heart rate by about 3 to 6 bpm, with larger increases in some patients [1]. The label says to avoid Vyvanse in people with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease or other serious cardiac disease [1]. It caps the dose at 50 mg a day in severe renal impairment (GFR 15 to under 30) and at 30 mg a day in end-stage renal disease [1]. For children, the label says patients who are not growing or gaining height or weight as expected may need treatment interrupted [1].